ReviewEye & contact lens2020
Biological Mechanisms of Atropine Control of Myopia.
Review in Eye & contact lens, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers, 11 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
83 citing papers in PubMed, 11 syntheses or guidelines pooled it, 162 citations in OpenAlex.
- Biological mechanisms of atropine in myopia control (Review).Molecular medicine reports · 2026Pooled it
- Dose-Dependent Effects of Atropine on Accommodative and Binocular Visual Function for Myopia Control in Children: A Systematic Review and Meta-Analysis.Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) · 2026Pooled it
- Low-concentration atropine for management of myopia progression: does iris colour matter?Eye (London, England) · 2026Pooled it
- Efficacy of interventions for myopia control in children: A systematic review with network meta-analyses.Acta ophthalmologica · 2025Pooled it
- Interventions for myopia control in children: a living systematic review and network meta-analysis.The Cochrane database of systematic reviews · 2025Pooled it
- A systematic review with meta-analysis on the efficacy of 0.01% atropine eyedrops in preventing myopia progression in worldwide children's populations.Frontiers in pharmacology · 2025Pooled it
- Myopia progression after cessation of atropine in children: a systematic review and meta-analysis.Frontiers in pharmacology · 2024Pooled it
- Interventions for myopia control in children: a living systematic review and network meta-analysis.The Cochrane database of systematic reviews · 2023Pooled it
- Comparison of the efficacy and safety of different doses of atropine for myopic control in children: a meta-analysis.Frontiers in pharmacology · 2023Pooled it
- The efficacy and safety of 0.01% atropine alone or combined with orthokeratology for children with myopia: A meta-analysis.PloS one · 2023Pooled it
- Efficacy and safety of atropine to control myopia progression: a systematic review and meta-analysis.BMC ophthalmology · 2020Pooled it
- Effect of 0.01% Atropine on Choroidal Thickness and Ocular Growth in Pre-myopic Children.Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) · 2026Trial
- Response of accommodation and vergence systems to low dose atropine.Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) · 2025Trial
- Dose Dependent Effects of Atropine on Static and Dynamic Pupil and Accommodation Metrics in Young Adults.Investigative ophthalmology & visual science · 2025Trial
- Ocular Surface Outcomes with Different 0.05% Atropine Dosing Frequencies in Children with Myopia: A Secondary Analysis of a Randomized Trial.Ophthalmology and therapy · 2026Article
- [Topical atropine for myopia prevention : Current study situation].Die Ophthalmologie · 2026Review
- Predictive value of early treatment response for long-term outcomes after seven years on low-dose atropine.BMJ open ophthalmology · 2026Article
- Global research trends of myopia in children and adolescents: A bibliometric review with hotspot visualization.Medicine · 2026Review
- Efficacy of low-concentration atropine (0.01%) in myopic shift in bilateral pediatric pseudophakia.Indian journal of ophthalmology · 2026Article
- Photopic pupil size, foveal anatomy and emmetropisation: a cross-sectional study in adult eyes.BMJ open ophthalmology · 2026Article
23 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myopia is a global problem that is increasing at an epidemic rate in the world. Although the refractive error can be corrected easily, myopes, particularly those with high myopia, are susceptible to potentially blinding eye diseases later in life. Despite a plethora of myopia research, the molecular/cellular mechanisms underlying the development of myopia are not well understood, preventing the search for the most effective pharmacological control. Consequently, several approaches to slowing down myopia progression in the actively growing eyes of children have been underway. So far, atropine, an anticholinergic blocking agent, has been most effective and is used by clinicians in off-label ways for myopia control. Although the exact mechanisms of its action remain elusive and debatable, atropine encompasses a complex interplay with receptors on different ocular tissues at multiple levels and, hence, can be categorized as a shotgun approach to myopia treatment. This review will provide a brief overview of the biological mechanisms implicated in mediating the effects of atropine in myopia control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.